BioAtla BCAB
OTC BCAB
$1.80 -0.01 (-0.55%)
At close: Nov 10, 2026 · 4:00 PM EST

BioAtla (BCAB) EBIT Margin (2020 - 2026)

Updated

BioAtla (BCAB) recorded EBIT Margin of 3.49% in Q2 2026.

Analysis

BioAtla (BCAB) EBIT Margin (2020 - 2026) Analysis & Trends

On a TTM basis, BioAtla's EBIT Margin came in at -377.94% as of Jun 30, 2026, up 157.98 percentage points year-over-year; for FY2025, it was -2965.25%, down 2293.04 percentage points from FY2024.

  • Annual EBIT Margin has a five-year change of +4050.83 percentage points (FY2020 to FY2025).
  • Across earlier years, EBIT Margin came in at -672.21% in FY2024 and -38576.00% in FY2021 (-31559.92 pp).
  • The Q2 2026 figure is the highest quarterly EBIT Margin in data going back to Q1 2020.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBIT Margin (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn 34.46%
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn 24.35%
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn 36.01%
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn 30.74%
5 Novartis Ag 311.58 Bn 285.16 Bn - -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn 29.12%
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn 35.79%
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn 41.71%
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn 32.98%
10 BioAtla 2.99 Mn -15.95 Mn - 3.49%
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 3.49%
Dec 31, 2025 -462.75%
Sep 30, 2024 -102.45%
Jun 30, 2024 -2,441.33%
Jun 30, 2021 -12,184.00%
Sep 30, 2020 -5,343.33%
Jun 30, 2020 -2,378.95%
Mar 31, 2020 -1,246.07%
API Access

BioAtla EBIT Margin API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=ebit-margin&ticker=BCAB&period=max&api_key=YOUR_API_KEY